Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Bramstedt – page 27

1 461 clinical trials in Bad Bramstedt, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Bramstedt at a glance
1 461
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 461 trials in Bad Bramstedt

Open in trial search

Aortic stenosis

Recruiting

Study of beta blockers in patients with aortic stenosis undergoing transcatheter aortic valve replacement

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Universitaetsspital Basel

Study of Atacicept Treatment for Patients with Multiple Autoimmune Glomerular Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Atacicept
  • Sponsor:Vera Therapeutics Inc.

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of Rilvegostomig with Bevacizumab and Tremelimumab as First-line Treatment for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:AstraZeneca AB

Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Study of visugromab and nivolumab with or without docetaxel as second-line treatment for patients with metastatic non-squamous non-small cell lung cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:CatalYm GmbH

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Bramstedt

What the registry says about research in the country

01 Autoimmune Disorders

Innovative research focusing on systemic sclerosis treatment, investigating a novel subcutaneous therapy aimed at reducing skin sclerosis symptoms. These trials are evaluating new therapeutic approaches for managing this challenging autoimmune condition.

  • Skin sclerosis management
  • Subcutaneous administration methods
  • Novel therapeutic compounds

The research emphasizes improving treatment options for patients with progressive skin hardening and tissue fibrosis.

02 Rare Blood Disorders

Clinical investigations targeting Hypereosinophilic Syndrome, examining the effectiveness of new subcutaneous treatments for patients with uncontrolled disease states while maintaining standard care protocols.

  • Blood disorder management
  • Treatment resistance
  • Standard of care optimization

These studies aim to provide better therapeutic options for patients with rare eosinophilic conditions.

03 Inflammatory Conditions

Advanced research into systemic lupus erythematosus treatment, focusing on disease activity reduction and exploring new therapeutic compounds for this complex autoimmune disorder.

  • Disease activity assessment
  • Treatment safety evaluation
  • Long-term efficacy monitoring

The studies employ comprehensive assessment tools to measure treatment effectiveness in lupus patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.